Brief: Antengene Corp Posts Full Year Loss Of RMB581.2 Mln
22/03/2024 10:38
March 22 (Reuters) - Antengene Corporation Ltd
6996.HK :
* EXPECT TO PUT MULTIPLE OF OUR PHASE I CLINICAL NOVEL
ASSETS INTO
EXPANSION AND PHASE II STAGE IN 2024
* LOSS FOR YEAR RMB581.2 MILLION VERSUS LOSS RMB601.5
MILLION
* FY REVENUE RMB67.3 MILLION VERSUS RMB160.1 MILLION
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106